• This record comes from PubMed

BK polyomavirus and valganciclovir: Highly suspected association urgently calling for a new randomized trial

. 2019 Dec ; 19 (12) : 3434-3435. [epub] 20191003

Language English Country United States Media print-electronic

Document type Letter, Research Support, Non-U.S. Gov't, Comment

Grant support
CZ.02.1.01/0.0/0.0 European Regional Development Fund - International
LO1503 Ministry of Education, Youth and Sports of the Czech Republic - International
Q39 Charles University Research Fund - International

Links

PubMed 31529778
DOI 10.1111/ajt.15598
PII: S1600-6135(22)09345-5
Knihovny.cz E-resources

Comment On

PubMed

Comment On

PubMed

See more in PubMed

Reischig T, Kacer M, Hes O, et al. Cytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathy. Am J Transplant. 2019;19(9):2457-2467.

Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant. 2008;8(1):69-77.

Reischig T, Kacer M, Jindra P, Hes O, Lysak D, Bouda M. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. Clin J Am Soc Nephrol. 2015;10(2):294-304.

Reischig T, Kacer M, Hruba P, et al. Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial. BMC Infect Dis. 2018;18(1):573.

Reischig T, Kacer M, Hes O, et al. Viral load and duration of BK polyomavirus viraemia determine renal graft fibrosis progression: histologic evaluation of late protocol biopsies [published online ahead of print 2019]. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfz061.

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...